Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agenus Inc. stock logo
AGEN
Agenus
$4.55
+1.8%
$5.10
$1.38
$7.34
$142.43M1.44373,695 shs381,014 shs
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
$0.38
-1.0%
$0.40
$0.22
$0.83
$15.05M3.01170,960 shs157,554 shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$9.75
-1.0%
$9.67
$2.20
$12.78
$269.57M-0.3631,553 shs12,807 shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$4.53
-3.0%
$4.80
$3.61
$10.35
$55.04M1.6172,702 shs74,559 shs
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
$1.88
$1.89
$0.58
$5.87
$98.94M0.752.46 million shs169,314 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agenus Inc. stock logo
AGEN
Agenus
+0.45%-11.83%-3.46%0.00%-26.48%
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-0.62%-0.62%-4.74%+23.13%-24.57%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-0.61%+4.68%-1.50%-0.10%+162.40%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
+3.78%-8.25%-0.85%-0.64%-54.79%
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agenus Inc. stock logo
AGEN
Agenus
$4.55
+1.8%
$5.10
$1.38
$7.34
$142.43M1.44373,695 shs381,014 shs
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
$0.38
-1.0%
$0.40
$0.22
$0.83
$15.05M3.01170,960 shs157,554 shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$9.75
-1.0%
$9.67
$2.20
$12.78
$269.57M-0.3631,553 shs12,807 shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$4.53
-3.0%
$4.80
$3.61
$10.35
$55.04M1.6172,702 shs74,559 shs
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
$1.88
$1.89
$0.58
$5.87
$98.94M0.752.46 million shs169,314 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agenus Inc. stock logo
AGEN
Agenus
+0.45%-11.83%-3.46%0.00%-26.48%
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-0.62%-0.62%-4.74%+23.13%-24.57%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-0.61%+4.68%-1.50%-0.10%+162.40%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
+3.78%-8.25%-0.85%-0.64%-54.79%
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agenus Inc. stock logo
AGEN
Agenus
2.50
Moderate Buy$14.50218.68% Upside
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
2.00
Hold$0.5032.28% Upside
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.80
Moderate Buy$14.7551.36% Upside
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
3.00
Buy$47.00937.53% Upside
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest DTIL, AGEN, ATHA, DBVT, and JNCE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$23.00
8/28/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$23.00
8/12/2025
Agenus Inc. stock logo
AGEN
Agenus
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$21.00
(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agenus Inc. stock logo
AGEN
Agenus
$101.71M1.43N/AN/A($13.06) per share-0.35
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/AN/AN/AN/A$1.16 per shareN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$4.15M64.34N/AN/A$1.42 per share6.86
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$68.70M0.78N/AN/A$6.87 per share0.66
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
$82M1.21N/AN/A$3.54 per share0.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agenus Inc. stock logo
AGEN
Agenus
-$227.21M-$7.15N/AN/AN/A-167.52%N/A-81.04%11/11/2025 (Estimated)
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-$96.94M-$1.55N/AN/AN/AN/A-139.40%-106.84%11/6/2025 (Estimated)
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$7.17M-$8.81N/AN/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/A

Latest DTIL, AGEN, ATHA, DBVT, and JNCE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Agenus Inc. stock logo
AGEN
Agenus
-$0.78-$1.00-$0.22-$1.00$49.71 million$25.70 million
8/7/2025Q2 2025
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-$0.18-$0.18N/A-$0.18N/AN/A
8/7/2025Q2 2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 million
7/29/2025Q2 2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agenus Inc. stock logo
AGEN
Agenus
N/AN/AN/AN/AN/A
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
N/AN/AN/AN/AN/A
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agenus Inc. stock logo
AGEN
Agenus
N/A
0.06
0.06
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/A
10.81
10.81
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
2.45
2.45
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
0.66
5.18
5.18
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
N/A
8.37
8.37

Institutional Ownership

CompanyInstitutional Ownership
Agenus Inc. stock logo
AGEN
Agenus
61.46%
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
57.12%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
71.74%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
37.99%
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
80.66%

Insider Ownership

CompanyInsider Ownership
Agenus Inc. stock logo
AGEN
Agenus
5.50%
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
22.10%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
1.44%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
4.50%
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
6.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agenus Inc. stock logo
AGEN
Agenus
44031.86 million30.11 millionOptionable
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
4039.44 million30.72 millionOptionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
8027.40 million27.00 millionOptionable
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
20011.79 million11.26 millionNo Data
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
13752.63 million48.99 millionOptionable

Recent News About These Companies

AdLib Media Group and Jounce Media Partner
2024 Jeep Gladiator Mojave Keeps On Truckin'
JNCE Jounce Therapeutics, Inc.
Buyout Offer Sends Jounce Jumping 20%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Agenus stock logo

Agenus NASDAQ:AGEN

$4.55 +0.08 (+1.79%)
Closing price 04:00 PM Eastern
Extended Trading
$4.53 -0.02 (-0.44%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Athira Pharma stock logo

Athira Pharma NASDAQ:ATHA

$0.38 0.00 (-0.97%)
Closing price 04:00 PM Eastern
Extended Trading
$0.39 +0.01 (+2.91%)
As of 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

DBV Technologies stock logo

DBV Technologies NASDAQ:DBVT

$9.74 -0.10 (-0.97%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Precision BioSciences stock logo

Precision BioSciences NASDAQ:DTIL

$4.53 -0.14 (-3.00%)
Closing price 04:00 PM Eastern
Extended Trading
$4.54 +0.01 (+0.22%)
As of 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Jounce Therapeutics stock logo

Jounce Therapeutics NASDAQ:JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.